---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000038"
form_type: "8-K/A"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:12:32.568360+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NovoCure discloses CEO Frank Leonard's pay: CHF 750K base, 90% target bonus, enhanced severance

## Summary
- Base salary of CHF 750,000 and target annual bonus of 90% of base (CHF 675,000).
- Eligible for equity awards under 2024 Omnibus Incentive Plan; relocation and tax indemnification provided.
- Severance on qualifying termination: 100% base salary; within 12 months post-change-in-control: 200% base + 200% target bonus plus full equity vesting.
- Non-compete covenant for 12 months after termination; perpetual non-disparagement.
- Amendment filed to supplement Dec. 1, 2025 8-K; compensation details now finalized.

## SEC filing metadata
- accession: 0001645113-26-000038
- form_type: 8-K/A
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000038/0001645113-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000038/nvcr-20251124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000038
- JSON: https://secwatch.observer/filing/0001645113-26-000038.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.